We are live on ! Find out more
CNSP icon

CNS Pharmaceuticals
CNSP

1 hedge funds and large institutions have $335K invested in CNS Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

44% more capital invested

Capital invested by funds: $232K → $335K (+$103K)

0% more funds holding

Funds holding: 1 → 1 (0)

0% more ownership

Funds ownership: 0% → 0% (+0%)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$550K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$81K
2
Bank of New York Mellon
Bank of New York Mellon
New York
-$36K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$23K
4
VF
Virtu Financial
New York
-$23K
5
TSS
Two Sigma Securities
New York
-$16K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$320K +$550K +4 New
TRCT
2
Tower Research Capital (TRC)
New York
$11K – – –
UBS Group
3
UBS Group
Switzerland
$2.91K – – –
Wells Fargo
4
Wells Fargo
California
$1.16K – – –
GRP
5
Global Retirement Partners
California
$82 – – –
Bank of America
6
Bank of America
North Carolina
$60 – – –
PNC Financial Services Group
7
PNC Financial Services Group
Pennsylvania
$20 – – –
GI
8
Gradient Investments
Minnesota
$17 – – –
PMFA
9
Plante Moran Financial Advisors
Michigan
$2 – – –
Vanguard Group
10
Vanguard Group
Pennsylvania
– -$81K -1 Closed
ACI
11
Alpha Cubed Investments
California
– -$2K – –
Bank of New York Mellon
12
Bank of New York Mellon
New York
– -$36K – –
Cambridge Investment Research Advisors
13
Cambridge Investment Research Advisors
Iowa
– -$5K – –
Commonwealth Equity Services
14
Commonwealth Equity Services
Massachusetts
– -$3K – –
FWA
15
FSM Wealth Advisors
Ohio
– -$7K – –
Geode Capital Management
16
Geode Capital Management
Massachusetts
– -$23K – –
Goldman Sachs
17
Goldman Sachs
New York
– -$3K – –
HighTower Advisors
18
HighTower Advisors
Illinois
– -$3K – –
Northern Trust
19
Northern Trust
Illinois
– -$6K – –
PCIA
20
Prime Capital Investment Advisors
Kansas
– -$2K – –
Renaissance Technologies
21
Renaissance Technologies
New York
– -$10K – –
State Street
22
State Street
Massachusetts
– -$4K – –
TSS
23
Two Sigma Securities
New York
– -$16K – –
VF
24
Virtu Financial
New York
– -$23K – –

CNSP Hedge Fund Activity: Q4 2022 in Review

1 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in CNS Pharmaceuticals (CNSP) for Q4 2022, worth a combined $335K — up 44% from $232K a quarter earlier.

Fund positioning in CNSP was balanced in Q4 2022: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $550K. The largest seller was Vanguard Group, exiting entirely with an estimated $81K sold.

  • 1 institutional investor held CNS Pharmaceuticals (CNSP) as of Q4 2022, unchanged from Q3 2022.
  • Funds reported $335K of CNS Pharmaceuticals stock for Q4 2022, up 44% quarter-over-quarter.
  • 1 fund opened new CNS Pharmaceuticals positions in Q4 2022 and 1 closed out, a net change of 0 holders.
  • The largest CNS Pharmaceuticals buyer in Q4 2022 was Armistice Capital, an estimated $550K added.
  • The largest CNS Pharmaceuticals seller in Q4 2022 was Vanguard Group, an estimated $81K sold.

Based on aggregated 13F filings for Q4 2022.